Ipsen acquired Epizyme, Inc., a US-based biotech company developing novel EZH2 inhibitors for cancer treatment, for USD 1.45 billion. This acquisition expanded Ipsen's oncology portfolio and added Tazverik® (tazemetostat), a first-in-class treatment for epithelioid sarcoma, to their pipeline.
Ipsen completed the acquisition of Albireo Pharma, Inc., a US-based leader in bile-acid modulators for rare liver diseases, for USD 42.00 per share plus a contingent value right. This acquisition strengthened Ipsen's rare disease portfolio with promising treatment for pediatric and adult cholestatic liver diseases and innovative pipeline potential.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5484
Published Date: Jan 03, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing demand for healthcare sector is the major factor driving the market growth.
The market size of blepharospasm treatment is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.
The major players in the market Allergan plc, Ipsen Pharma, Medytox Inc., Revance Therapeutics, Inc., Merz Pharma GmbH & Co. KGaA, US WorldMeds, LLC, and others.
The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.